Shopping Cart 0
Cart Subtotal
USD 0

Intrexon Corp (XON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural biotech, animal sciences, and industrial products division. Its cell engineering unit designs and creates cell systems and optimize processes for the development of biologically based products to address unmet market needs. Intrexon's IT division includes infrastructure, software engineering, and information systems. The company's agricultural biotech division provides food and feed crops for a variety of applications in agriculture. It has partnership with the channel of network collaborators and joint ventures to commercialize its technologies. Intrexon is headquartered in Blacksburg, Virginia, the US.

Intrexon Corp (XON)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12

Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Intrexon Corp, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Intrexon Acquires Laboratory Operations From Codexis USD 1.5 Million 16

Venture Financing 17

Intrexon Raises USD57.5 Million in Venture Financing 17

Intrexon Raises USD29 Million in Venture Financing 18

Intrexon Raises USD 75 Million In Extended Series F Financing 19

ActoGeniX Raises USD 14 Million In Series B Financing 20

Intrexon Raises Additional USD 25 Million In Series F Financing 22

Medistem Raises Funds Through Venture Financing 23

Partnerships 24

Intrexon and Arch Pharmalabs Enter into Agreement 24

Intrexon and Johnson Matthey Enter into Agreement 25

ZIOPHARM, Intrexon Enter into Agreement with NCI 26

Intrexon Forms Joint Venture with White Rock Capital Partners 27

Intrexon Partners with Relieve Genetics 28

Intrexon Partners with Exotech Bio 29

Fibrocell Science Enters into Agreement with Intrexon 30

Intrexon Enters into Research Agreement with Janssen Pharma 31

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 32

Intrexon Enters into Partnership with Synthetic Biologics 33

Intrexon Enters into Co-Development Agreement with Oragenics 34

Intrexon Enters into R&D Agreement with National Cancer Institute 35

Ziopharm Expands Co-Development Agreement with Intrexon 36

Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 37

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 38

OvaScience Forms Joint Venture With Intrexon 39

Stallergenes Enters Into Co-Development Agreement With ActoGeniX 40

Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 42

Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 44

Soligenix Enters Into Co-Development Agreement With Intrexon 45

Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 47

ActoGeniX Enters Into Research Agreement With Merck 48

Fibrocell Science Enters Into Co-Development Agreement With Intrexon 49

Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 50

Fibrocell Science Amends Co-Development Agreement with Intrexon 51

Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 52

Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 53

BioLife Cell Bank Enters Into Research Agreement With Intrexon 54

Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 55

Licensing Agreements 56

Genten Therapeutics Enters Into Licensing Agreement With Intrexon 56

CRS Bio Enters into Licensing Agreement with Intrexon 57

Fibrocell Science Enters into Licensing Agreement with Intrexon 58

Intrexon Enters into Licensing Agreement with Merck Serono 60

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 61

Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 63

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 65

ERCell Enters into Licensing Agreement with Medistem 67

Medistem Enters Into Licensing Agreement With Cytori Therapeutics 68

Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 69

Equity Offering 70

Intrexon to Raise USD100 Million in Public Offering of Shares 70

Intrexon Raises USD86.2 Million in Public Offering of Shares 71

Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 73

Oragenics Raises USD4.7 Million in Private Placement of Shares 74

Intrexon Raises USD230 Million in Public Offering of Shares 76

Intrexon Raises USD116.4 Million in Public Offering of Shares 78

Oragenics Completes Private Placement Of Shares For USD 4 Million 80

Intrexon Completes IPO Of Shares For USD 184 Million 81

Debt Offering 82

Intrexon Raises USD200 Million in Public Offering 3.50% Convertible Senior Notes Due 2023 82

Acquisition 83

Intrexon Acquires GenVec 83

Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 85

Intrexon Acquires Remaining 41% Stake in Exemplar Genetics 86

Intrexon Acquires ActoGeniX 87

Intrexon Acquires 51% Stake in Exemplar Genetics 89

Intrexon Completes Acquisition Of MediStem For USD 26 Million 90

Intrexon Corp-Key Competitors 91

Intrexon Corp-Key Employees 92

Intrexon Corp-Locations And Subsidiaries 93

Head Office 93

Other Locations & Subsidiaries 93

Joint Venture 94

Recent Developments 95

Strategy And Business Planning 95

Mar 10, 2017: Intrexon Creates Precigen and Accelerates Strategic Review of Structural Options Related to Health Assets 95

Financial Announcements 96

May 10, 2018: Intrexon Announces First Quarter 2018 Financial Results 96

Mar 01, 2018: Intrexon Announces Fourth Quarter and Full Year 2017 Financial Results 99

Nov 09, 2017: Intrexon Announces Third Quarter 2017 Financial Results 102

Aug 09, 2017: Intrexon Announces Second Quarter and First Half 2017 Financial Results 105

May 10, 2017: Intrexon Announces First Quarter 2017 Financial Results 107

Mar 01, 2017: Intrexon Announces Fourth Quarter and Full Year 2016 Financial Results 109

Corporate Communications 112

Nov 27, 2017: Intrexon Announces Key Management Appointments 112

Jun 29, 2017: Intrexon Appoints Helen Sabzevari, Ph.D., Senior Vice President, Human Therapeutics and Head of Research and Development of Precigen 114

Apr 27, 2017: Intrexon Appoints Vinita Gupta, Leading Pharma Executive, to its Board of Directors 115

Other Significant Developments 116

Aug 09, 2018: Intrexon business update and conference call 116

May 29, 2018: Isolation and Recombinant Expression of Key Enzyme for Opioid Production 118

Appendix 119

Methodology 119

About GlobalData 119

Contact Us 119

Disclaimer 119


List Of Figure

List of Figures

Intrexon Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Intrexon Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Intrexon Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Intrexon Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Intrexon Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Intrexon Corp, Deals By Therapy Area, 2012 to YTD 2018 11

Intrexon Corp, Medical Devices Deals, 2012 to YTD 2018 12

Intrexon Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Intrexon Acquires Laboratory Operations From Codexis USD 1.5 Million 16

Intrexon Raises USD57.5 Million in Venture Financing 17

Intrexon Raises USD29 Million in Venture Financing 18

Intrexon Raises USD 75 Million In Extended Series F Financing 19

ActoGeniX Raises USD 14 Million In Series B Financing 20

Intrexon Raises Additional USD 25 Million In Series F Financing 22

Medistem Raises Funds Through Venture Financing 23

Intrexon and Arch Pharmalabs Enter into Agreement 24

Intrexon and Johnson Matthey Enter into Agreement 25

ZIOPHARM, Intrexon Enter into Agreement with NCI 26

Intrexon Forms Joint Venture with White Rock Capital Partners 27

Intrexon Partners with Relieve Genetics 28

Intrexon Partners with Exotech Bio 29

Fibrocell Science Enters into Agreement with Intrexon 30

Intrexon Enters into Research Agreement with Janssen Pharma 31

Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 32

Intrexon Enters into Partnership with Synthetic Biologics 33

Intrexon Enters into Co-Development Agreement with Oragenics 34

Intrexon Enters into R&D Agreement with National Cancer Institute 35

Ziopharm Expands Co-Development Agreement with Intrexon 36

Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 37

Intrexon Enters Into R&D Agreement With Johnson & Johnson Innovation For Skin And Hair Products 38

OvaScience Forms Joint Venture With Intrexon 39

Stallergenes Enters Into Co-Development Agreement With ActoGeniX 40

Stallergenes Exercises Option for Co-Development Agreement with ActoGeniX 41

Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 42

Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 44

Soligenix Enters Into Co-Development Agreement With Intrexon 45

Sanford-Burnham Medical Enters Into Agreement With Intrexon For Stem Cell Research 47

ActoGeniX Enters Into Research Agreement With Merck 48

Fibrocell Science Enters Into Co-Development Agreement With Intrexon 49

Fibrocell Science And Intrexon Expand Co-Development Agreement For Potential New Class Of Therapeutics 50

Fibrocell Science Amends Co-Development Agreement with Intrexon 51

Medistem Enters Into Agreement With Superview Biotechnology To Develop Antibodies For Regenerative Therapies 52

Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 53

BioLife Cell Bank Enters Into Research Agreement With Intrexon 54

Medistem Enters Into Co-Development Agreement With Shanghai Jia Fu Medical Apparatus 55

Genten Therapeutics Enters Into Licensing Agreement With Intrexon 56

CRS Bio Enters into Licensing Agreement with Intrexon 57

Fibrocell Science Enters into Licensing Agreement with Intrexon 58

Intrexon Enters into Licensing Agreement with Merck Serono 60

Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 61

Soligenix Enters Into Licensing Agreement With Intrexon To Develop Melioidosis Therapy 63

Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 65

ERCell Enters into Licensing Agreement with Medistem 67

Medistem Enters Into Licensing Agreement With Cytori Therapeutics 68

Medistem Enters Into Licensing Agreement With Yale University For Type 1 Diabetes 69

Intrexon to Raise USD100 Million in Public Offering of Shares 70

Intrexon Raises USD86.2 Million in Public Offering of Shares 71

Intrexon to Raise USD100 Million in Private Placement of Preferred Shares 73

Oragenics Raises USD4.7 Million in Private Placement of Shares 74

Intrexon Raises USD230 Million in Public Offering of Shares 76

Intrexon Raises USD116.4 Million in Public Offering of Shares 78

Oragenics Completes Private Placement Of Shares For USD 4 Million 80

Intrexon Completes IPO Of Shares For USD 184 Million 81

Intrexon Raises USD200 Million in Public Offering 3.50% Convertible Senior Notes Due 2023 82

Intrexon Acquires GenVec 83

Intrexon Acquires 100% Stake in Okanagan Specialty Fruits 85

Intrexon Acquires Remaining 41% Stake in Exemplar Genetics 86

Intrexon Acquires ActoGeniX 87

Intrexon Acquires 51% Stake in Exemplar Genetics 89

Intrexon Completes Acquisition Of MediStem For USD 26 Million 90

Intrexon Corp, Key Competitors 91

Intrexon Corp, Key Employees 92

Intrexon Corp, Subsidiaries 93

Intrexon Corp, Joint Venture 94

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Intrexon Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.